Biofrontera AGFRA:B8FK 56 EBITDA Margin % is 1.27% as of Mar. 2026. GuruFocus rates FRA:B8FK with a GF Score™ of 56/100 and a GF Value™ of €2.29 (Fairly Valued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Biofrontera AG ranks worse than 78.64% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biofrontera AG's EBITDA for the
three
months ended in Mar. 2026 was €0.05 Mil. Biofrontera AG's Revenue for the
three
months ended in Mar. 2026 was €3.71 Mil. Therefore, Biofrontera AG's EBITDA margin for the quarter that ended in Mar. 2026 was 1.27%.
Biofrontera AG (FRA:B8FK) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Biofrontera AG EBITDA Margin % Related Terms
Biofrontera AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:B8FK vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera AG (FRA:B8FK) has a EBITDA Margin % of 1.27% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biofrontera AG and its competitors. According to the industry distribution chart, Biofrontera AG ranks #751 out of 955 companies in the Drug Manufacturers industry, placing it in the top 78.6%.
Is Biofrontera AG's EBITDA Margin % too high?
Biofrontera AG's current EBITDA Margin % is 1.27%. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Biofrontera AG's value of 1.27% is 89.8% below this industry median. Based on the distribution chart, Biofrontera AG ranks #751 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biofrontera AG has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #751 out of 955 companies for EBITDA Margin %. This places Biofrontera AG in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Biofrontera AG's value of 1.27% is 89.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera AG's current EBITDA Margin % of 1.27% is 89.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biofrontera AG and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera AG's current EBITDA Margin % is 1.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera AG (FRA:B8FK) is currently considered Fairly Valued. The stock's GF Value™ is €2.29, compared to a current price of €2.21 — trading 3.5% below its estimated fair value. The current EBITDA Margin % is 1.27% and 89.8% below the Drug Manufacturers industry median of 12.44. Biofrontera AG's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Biofrontera AG (FRA:B8FK), the current EBITDA Margin % is 1.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (FRA:B8FK) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued.
The current stock price of €2.21 is trading 3.5% below its estimated GF Value™ of €2.29.
GuruFocus considers Biofrontera AG to be Fairly Valued.
Key valuation signals for FRA:B8FK:
EBITDA Margin %: 1.27%
GF Value™: €2.29 vs. price of €2.21 (3.5% below fair value)
Industry Position: 89.8% below the Drug Manufacturers median (#751 of 955)
No single metric tells the full story. See the FRA:B8FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
56GF Score
Get the complete analysis for FRA:B8FK
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B8FK has been successfully added to your 
